Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Seelos Therapeutics, Inc.

Company calendar

Market Closed - OTC Markets 12:25:32 2026-06-01 pm EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	+9,900.00%

Dec. 28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 90.66K 84.51K 76.66K 145K 9.68M 145K 1.02M 398K 5M 380K 372K 16.08M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 10.15M 9.46M 8.58M 16.18M 1.08B 16.28M 114M 44.49M 559M 42.57M 41.63M 1.8B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	100%	Yield 2022 *	-	Yield 2023	-

Dec. 28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news: Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Annual profits - Rate of surprise

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		848.64
5 years	0		9,561.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/29/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
1/12/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
1/12/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	+9,900.00%	-100.00%	136
WUXI APPTEC CO., LTD.	+0.03%	-5.67%	+50.74%	+79.07%	70.61B
ARGENX SE	+0.66%	-10.08%	+6.97%	+54.49%	51.01B
LONZA GROUP AG	+0.31%	+1.49%	+8.84%	+32.81%	48.1B
IQVIA HOLDINGS INC.	+0.90%	-1.46%	+28.68%	+32.69%	42.78B
REVOLUTION MEDICINES, INC.	+2.21%	-6.61%	+297.85%	+701.45%	40.67B
BEONE MEDICINES AG	-1.15%	-3.11%	+7.15%	+98.83%	40.3B
CELLTRION, INC.	+0.45%	-1.20%	+9.11%	+46.80%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-2.23%	-3.48%	+39.06%	+12.14%	28.16B
BIONTECH SE	-1.16%	-1.84%	-6.31%	-11.99%	24.36B
Average	+990.00%	-2.22%	+1,034.21%	+94.63%	37.66B
Weighted average by Cap.	+0.15%	-2.73%	+51.03%	+120.38%

	2022	2023
Net sales	-	2.2 1.97 1.84 1.67 3.15 210.59 3.16 22.09 8.65 108.67 8.28 8.09 349.71
Net income	-73.53M -65.83M -61.37M -55.66M -105M -7.03B -106M -737M -289M -3.63B -276M -270M -11.67B	-37.88M -33.91M -31.61M -28.67M -54.08M -3.62B -54.42M -380M -149M -1.87B -142M -139M -6.01B
Net Debt	4.59M 4.11M 3.83M 3.47M 6.55M 439M 6.59M 46.02M 18.02M 226M 17.24M 16.86M 728M	11.23M 10.05M 9.37M 8.5M 16.04M 1.07B 16.14M 113M 44.1M 554M 42.19M 41.26M 1.78B